Diseases / Retinal Vein Occlusion
Retinal Vein Occlusion Clinical Trials
DiseaseRetinal vein occlusion is a vascular eye disease caused by blockage of retinal venous outflow, leading to retinal hemorrhage, edema, and vision loss. Major subtypes are branch and central retinal vein occlusion.
Continuously tracked·last revised
Data: CSV·JSON·Browse the trials
Follow Retinal Vein Occlusion
Email me when this page changes — new trials, changes of phase or status, and results as they are posted.
No mail is going out yet — your address is recorded now, used for nothing else, and never shared.
Thanks — your request is recorded. No mail is sent yet.
That did not work. Check the address and try again.
Recruiting Phase 3
| Trial | Phase | Status | Sponsor | Started |
|---|---|---|---|---|
| Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion NCT07259928 | Phase 2 | Recruiting | Annexin Pharmaceuticals AB | Started 2025-11 |
| A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO NCT07205887 | Phase 2 | Recruiting | EyeBiotech Ltd. | Started 2025-09 |
Recently started
Results recently posted
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 1 | — | — | — | 2 | — | — | 1 | 4 |
| Phase 1 | — | 1 | — | — | 9 | 3 | 1 | 5 | 19 |
| Phase 1/2 | — | — | — | — | 13 | — | 1 | — | 14 |
| Phase 2 | 2 | — | — | — | 17 | 2 | 1 | 8 | 30 |
| Phase 2/3 | — | — | — | — | 3 | 1 | — | 3 | 7 |
| Phase 3 | — | — | — | 2 | 35 | 7 | — | 2 | 46 |
| Phase 4 | 1 | 1 | 1 | — | 20 | 4 | — | 7 | 34 |
| Not applicable | 3 | 2 | — | 3 | 23 | 5 | 1 | 13 | 50 |
| Unknown | 3 | 5 | 1 | 3 | 41 | 2 | 1 | 14 | 70 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Retinal Vein Occlusion | 4 | 19 | 14 | 30 | 7 | 46 | 34 | 50 | 70 | 274 |
| Macular Edema | 1 | 7 | 7 | 12 | 1 | 33 | 17 | 13 | 22 | 113 |
| Macular Degeneration | 1 | 4 | 2 | 4 | 1 | 3 | 8 | 11 | 22 | 56 |
| Diabetic Retinopathy | 1 | 2 | — | 5 | — | — | 2 | 10 | 18 | 38 |
| Vision Disorders | — | 1 | — | 1 | — | 11 | 3 | 1 | — | 17 |
| Retinal Diseases | 2 | 2 | 1 | 1 | — | 2 | 1 | 1 | 5 | 15 |
| Choroidal Neovascularization | — | 2 | — | 1 | — | 1 | 2 | 2 | 1 | 9 |
| Retinal Artery Occlusion | — | — | — | — | — | — | 1 | 3 | 5 | 9 |
| Glaucoma | — | — | 1 | — | — | — | — | 3 | 4 | 8 |
| Wet Macular Degeneration | — | 1 | — | 2 | — | 3 | 1 | — | 1 | 8 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Novartis Pharmaceuticals | 19 | 10 |
| 2 | Allergan | 16 | 2 |
| 3 | Bayer | 8 | 1 |
| 4 | National Eye Institute (NEI) | 7 | 2 |
| 5 | Assiut University | 4 | 0 |
| 6 | Clearside Biomedical, Inc. | 4 | 2 |
| 7 | Hoffmann-La Roche | 4 | 2 |
| 8 | Medical University of Vienna | 4 | 1 |
| 9 | Shahid Beheshti University of Medical Sciences | 4 | 1 |
| 10 | Barnes Retina Institute | 3 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Ranibizumab | 60 |
| 2 | aflibercept | 34 |
| 3 | Dexamethasone | 22 |
| 4 | Bevacizumab | 20 |
| 5 | Calcium Dobesilate | 18 |
| 6 | salicylhydroxamic acid | 13 |
| 7 | Triamcinolone Acetonide | 8 |
| 8 | faricimab | 5 |
| 9 | Triamcinolone | 4 |
| 10 | brolucizumab | 3 |
Terminations
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT04847869 Terminated | Terminated | Poor efficacy of treatment | 2024-07-31 |
| NCT04707625 Terminated | Terminated | IRB stopped study due to safety concerns. No further data collection and what has been collected is not appropriate for analysis. | 2023-12-18 |
| NCT04563299 Terminated | Terminated | Subject Enrollment | 2023-02-14 |
| NCT03790852 Terminated | Terminated | All patients past planned primary endpoint; decision by Sponsor to wind down open-label follow-up activities. | 2022-06-09 |
| NCT02088151 Terminated | Terminated | Suitable device for laser no longer available | 2022-02-01 |
| NCT05127525 Terminated | Terminated | Adverse event | 2022-01-31 |
| NCT03417401 Withdrawn | Withdrawn | organizationally not yet possible | 2021-12-10 |
| NCT03802630 Terminated | Terminated | Study was terminated by sponsor due to increased incidences of AEs of special interest (intraocular inflammation including retinal vasculitis and retinal vascular occlusion), in patients dosed brolucizumab 6mg every 4 weeks beyond 3 initial doses | 2021-07-26 |
| NCT03810313 Terminated | Terminated | Study was terminated by sponsor due to increased incidences of adverse events of special interest (intraocular inflammation including retinal vasculitis, and retinal vascular occlusion), in patients dosed every 4 weeks beyond 3 initial doses. | 2021-07-26 |
| NCT01875770 Terminated | Terminated | The study was terminated as patients could not be followed-up during the COVID pandemic. Since this was a non-intervention study, as per Johns Hopkins University policy, we had to hold off the patient visits during the pandemic. | 2021-03-03 |
Evidence
- Results reported
- 47.2%77 of 163 completed
- Published
- 10.4%17 of 163 completed
- Primary endpoint met
- 30.6%15 of 49 analyses
- Median months to report
- 14
Documents disclosed
Trial profile
- Median enrollment
- 60
- Median duration
- 27months
- Countries
- 67
- Study sites
- 2204
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 20
- Phase 1
- 20
- Phase 1/2
- 20
- Phase 2
- 32
- Phase 2/3
- 38
- Phase 3
- 243
- Phase 4
- 50
- Not applicable
- 46
- Unknown
- 153
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Paris | France | 21 |
| 2 | San Antonio | United States | 20 |
| 3 | Abilene | United States | 18 |
| 4 | Beijing | China | 17 |
| 5 | Hagerstown | United States | 17 |
| 6 | Phoenix | United States | 16 |
| 7 | Austin | United States | 15 |
| 8 | Houston | United States | 15 |
| 9 | Shanghai | China | 15 |
| 10 | Wuhan | China | 15 |